a result of various important factors, including risks relating to: our plans to develop and commercialize EXPAREL; the success and timing of our commercial launch of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our commercialization and marketing capabilities; and other factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2010, and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3560
Pure Communications Inc.
Jennifer Beugelmans, 646-596-7473Pacira Pharmaceuticals, Inc.Consolidated Statement of Operations(unaudited)(in thousands, except share and per share amounts)Three Months
Ended September 30, Nine Months
Ended September 30, 2011201020112010 Revenues: Supply revenue
9221,0232,7432,693 Collaborative licensing and development revenue
1,3527653,8452,551 Total revenues
3,9564,53211,45612,371 Operating expenses: Cost of revenues
3,3573,57310,13810,168 Research and development
4,3445,71612,23714,954 Selling, general and administrative
4,9881,69413,4653,948 Total operating expenses
Page: 1 2 3 4 5 6 7 8 9 Related medicine technology :1
|SOURCE Pacira Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress2
. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)3
. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment4
. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management5
. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting6
. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering7
. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting8
. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting9
. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference10
. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results11
. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference